Holen Sie sich die Stockscreener-App
12.98
6.89%
-0.96
Schlusskurs vom Vortag:
$13.94
Offen:
$13.68
24-Stunden-Volumen:
41,717
Relative Volume:
0.36
Marktkapitalisierung:
$203.06M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-4.2557
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+26.88%
1M Leistung:
+57.91%
6M Leistung:
+37.50%
1J Leistung:
-48.66%
1-Tages-Spanne:
$12.74
$14.09
1-Wochen-Bereich:
$10.35
$14.09
52-Wochen-Spanne:
$5.6652
$27.84
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
12.98 | 203.06M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.83 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.29 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.14 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
588.61 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.96 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of “Hold” from Analysts - Defense World
RAPT Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital gains - jammulinksnews.com
What drives RAPT Therapeutics Inc. stock pricePhenomenal trading returns - Autocar Professional
What analysts say about RAPT Therapeutics Inc. stockFree Stock Selection - jammulinksnews.com
RAPT Therapeutics: LifeSci Capital initiates Outperform with $31 PT. - AInvest
What makes RAPT Therapeutics Inc. stock price move sharplyFree Access to Investment Community - Newser
Is RAPT Therapeutics Inc. a good long term investmentHigh-performance investment picks - jammulinksnews.com
How RAPT Therapeutics Inc. stock performs during market volatilityTop Performer Shortlist - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionSafe Entry High Exit Alerts - Newser
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why - Yahoo Finance
RAPT Therapeutics Explodes 20%—What's Fueling the Surge? - AInvest
RAPT Therapeutics Soars 24%—What’s Fueling the Breakout? - AInvest
Best Momentum Stocks to Buy for July 15th - TradingView
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect? - Yahoo Finance
HC Wainwright Analysts Decrease Earnings Estimates for RAPT - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) Stock - Defense World
Rapt Therapeutics (NASDAQ:RAPT) Price Target Raised to $27.00 - Defense World
H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Cuts Target Price to $27 - 富途牛牛
RAPT Therapeutics Unveils Plans for RPT904 Development - TipRanks
Rapt Therapeutics (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Expands Board with New Appointments - TipRanks
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know - Yahoo Finance
RAPT Therapeutics Executes 1-for-8 Reverse Stock Split - TipRanks
RAPT Therapeutics (RAPT) Trading Halted as News Awaits Release | RAPT Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Rapt Therapeutics announces effective date for 1-for-8 reverse stock split - Yahoo Finance
# RAPT Therapeutics to implement 1-for-8 reverse stock split By Investing.com - Investing.com South Africa
RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025 - Nasdaq
RAPT Therapeutics Shares to Start Trading on a Split-Adjusted Basis Tuesday - marketscreener.com
RAPT Therapeutics Announces Effective Date For 1-For-8 Reverse Stock Split - MarketScreener
RAPT Therapeutics Announces Reverse Stock Split Effective June 2025 | RAPT Stock News - GuruFocus
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.28%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):